IRulya Therapeutics presents Phase 2a data in pulmonary hypertension
IRLA•IRulya Therapeutics reported a mean 67.4-meter improvement in six-minute walk distance at 24 weeks among four evaluable Phase 2a PH-ILD patients. The company also outlined upcoming trial milestones and said it raised $115 million upfront in May 2026.
1. Phase 2a results
Four evaluable Phase 2a PH-ILD patients recorded a mean 67.4-meter improvement in six-minute walk distance at 24 weeks.
2. Trial and funding plans
IRulya Therapeutics expects Phase 2 data for inhaled rapamycin LAM-001 in bronchiolitis obliterans syndrome in the first quarter of 2027. Its ongoing Phase 2b PH-ILD trial targets 75 patients, with data anticipated in the first quarter of 2028. A Phase 2 trial in sarcoidosis-associated pulmonary hypertension is expected to start in the fourth quarter of 2026, with data anticipated in late 2028. The company said an oversubscribed financing raised $115 million upfront in May 2026.
